As the main implementation entity of the group's pharmaceutical intermediate business, the company undertakes the research and development function of the drug marketing authorization holder platform construction project. We will focus on tackling intermediate technologies for cephalosporin antibiotics and have developed patented preparation processes for products such as cefotaxime and cefuroxime. The MAH project launched in 2020 involves full process research and development services such as drug synthesis process research and registration application material preparation.